![[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis](https://news.medxy.ai/wp-content/uploads/2025/11/9d3c0201-d1b3-49f2-a408-3ea3d0347451-1024x585.jpg)
[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis
PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.
